Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.44 |
| ▸ | MMP13 | P45452 | 10/20 | 0.43 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6706809 | 0.95 | MMP13 (0.42) | GRM5MMP13SLC22A8DRD3KCNH2 | |
| SCHEMBL6706842 | 0.94 | MMP13 (0.48) | GRM5MMP13SLC22A8 | |
| SCHEMBL6706100 | 0.92 | MMP13 (0.42) | GRM5MMP13SLC22A8 | |
| SCHEMBL6706890 | 0.92 | MMP13 (0.55) | GRM5MMP13SLC22A8FFAR1FFAR4 | |
| SCHEMBL5697101 | 0.91 | MMP13 (0.41) | GRM5MMP13SLC22A8 | |
| SCHEMBL6915307 | 0.90 | MMP13 (0.39) | GRM5MMP13SLC22A8DRD3KCNH2 | |
| SCHEMBL6706967 | 0.90 | MMP13 (0.38) | GRM5MMP13SLC22A8FFAR1FFAR4 | |
| SCHEMBL6704965 | 0.85 | MMP13 (0.42) | GRM5MMP13SLC22A8FFAR1FFAR4 | |
| SCHEMBL6705933 | 0.82 | POLB (0.39) | MMP13DRD3KCNH2 | |
| SCHEMBL6708293 | 0.82 | PKM (0.38) | GRM5MMP13FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043986-A1 | 5,6-Fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors | NAHRA JOE (US) | 2004-03-04 | — | — | US | claimed |
| WO-2004014869-A2 | 5,6-FUSED 3,4-DIHYDROPYRIMIDINE-2-ONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | claimed |
| US-20040043986-A1 | 5,6-Fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors | NAHRA JOE (US) | 2004-03-04 | — | — | US | disclosed |
| WO-2004014869-A2 | 5,6-FUSED 3,4-DIHYDROPYRIMIDINE-2-ONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043986-A1 | 5,6-Fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors | MMP9, MMP13, MMP25 | GRM5 672/4885MMP13 2/4885SLC22A8 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.